Buy this book
![Loading indicator](/images/ajax-loader-bar.gif)
This edition doesn't have a description yet. Can you add one?
Buy this book
![Loading indicator](/images/ajax-loader-bar.gif)
Showing 1 featured edition. View all 1 editions?
Edition | Availability |
---|---|
1
Economic assessment: celecoxib and rofecoxib for patients with osteoarthritis or rheumatoid arthritis
2002, Canadian Coordinating Office for Health Technology Assessment
in English
|
aaaa
|
Book Details
Edition Notes
This overview is based on the technology report no. 23 entitled Cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis by A. Maetzel, M.D. Krahn and G. Naglie.--Cf. t. p.
"Bruce Brady and Michel Boucher (CCOHTA) are acknowledged for their significant contribution in the preparation of this overview".
At head of title: The Canadian Coordinating Office for Health Technology Assessment.
"February 2002".
Includes bibliographical references.
Classifications
The Physical Object
ID Numbers
Community Reviews (0)
Feedback?January 21, 2010 | Edited by WorkBot | add subjects and covers |
December 11, 2009 | Created by WorkBot | add works page |